Location History:
- Fairfax, VA (US) (1990)
- Silver Spring, MD (US) (1992 - 2000)
- Bethesda, MD (US) (1990 - 2014)
- Rockville, MD (US) (2002 - 2017)
Company Filing History:
10 out of 3,539 
6 out of 1,217 
4 out of 2,202 
Years Active: 1990-2017
Title: David J FitzGerald: Innovator in Antibody Therapeutics and Cytotoxic Agents
Introduction: David J FitzGerald is a renowned inventor based in Rockville, MD, who has made significant contributions to the field of biotechnology. With a remarkable portfolio of 21 patents, he is recognized for his pioneering work in recombinant antibodies and innovative therapeutic approaches targeting malignancies.
Latest Patents: FitzGerald's latest patents include groundbreaking developments in the realm of immunotherapy. One of his notable inventions is focused on recombinant antibodies and immunoconjugates that are specifically targeted to CD-22 bearing cells and tumors. This invention not only provides high binding affinity anti-CD22 antibodies but also includes immunoconjugates associated with therapeutic agents, such as exotoxins or detectable labels. These advances have potential applications in diagnostics and inhibitory methods for malignant B cells.
Another significant patent involves the development of mutated, cytotoxic forms of Pseudomonas exotoxin A (PE). This invention features a furin cleavage sequence that is conjugated or fused to specific residues of PE, resulting in minimal forms that are smaller than traditional cytotoxic forms. These innovations reduce non-specific toxicity and enhance safety by lowering the immunogenicity due to domain II or domain Ib of PE. Additionally, this patent encompasses the nucleic acids encoding these PEs, along with chimeric molecules that utilize these components.
Career Highlights: Throughout his career, FitzGerald has collaborated with esteemed institutions such as the United States Department of Health and Human Services. His work has positioned him as a key figure in the advancement of medical therapies aimed at treating cancer and other diseases.
Collaborations: FitzGerald has worked alongside prominent professionals in the field, including Ira H Pastan and Vijay K Chaudhary. These collaborations have further enriched his research and contributed to the innovation of life-saving treatments.
Conclusion: David J FitzGerald stands out as a leading inventor whose work in antibody therapies and cytotoxic agents has paved the way for new and effective treatment options. His extensive patent portfolio is a testament to his dedication to advancing medical science and improving patient outcomes.